Ipsen S.A. (EPA:IPN)
162.70
-6.10 (-3.61%)
Jul 10, 2026, 5:35 PM CET
Ipsen Revenue
In the year 2025, Ipsen had annual revenue of 3.93B EUR with 9.92% growth. Ipsen had revenue of 1.99B in the half year ending December 31, 2025.
Revenue
3.93B
Revenue Growth
+9.92%
P/S Ratio
3.40
Revenue / Employee
709.88K
Employees
5,535
Market Cap
13.36B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.93B | 354.70M | 9.92% |
| Dec 31, 2024 | 3.57B | 268.10M | 8.11% |
| Dec 31, 2023 | 3.31B | 150.00M | 4.75% |
| Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
| Dec 31, 2021 | 2.75B | 62.40M | 2.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 47.35B |
| EssilorLuxottica Société anonyme | 28.49B |
| Eurofins Scientific SE | 7.30B |
| emeis Société anonyme | 5.90B |
| Ramsay Générale de Santé | 5.36B |
| Clariane SE | 5.31B |
| bioMérieux | 4.07B |
| Sartorius Stedim Biotech | 2.98B |
Ipsen News
- 1 day ago - Ipsen Reports Reduced Migraine Days With Dysport In Phase 3 BEOND Topline Data - Nasdaq
- 7 days ago - Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree - WSJ
- 8 days ago - Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal - Nasdaq
- 9 days ago - Ipsen Acquires Memo Therapeutics for Over â¬700 Million - GuruFocus
- 9 days ago - Ipsen To Acquire Memo Therapeutics For Over 700 Mln Euros, Expanding Rare Disease Portfolio - Nasdaq
- 9 days ago - Ipsen (IPSEY) to Acquire Memo Therapeutics for Over â¬700M - GuruFocus
- 9 days ago - Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million - WSJ
- 9 days ago - Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio - GlobeNewsWire